Allurion Faces Restatement, France Suspension and Refinancing Amid Cash Burn and Delisting Risk

Allurion Technologies, Inc. (NYSE: ALUR)

Quick take - straight to the point: the company is in active remediation and refinancing mode. It restated Q2 2024 results because of control failures, completed a 1-for-25 reverse split, replaced a term loan with convertible notes from RTW, and is dealing with a regulatory suspension in France. Financials show decent gross margins but persistent net losses, volatile non‑cash fair‑value swings and shrinking cash.

Key facts & metrics (as reported / restated)

* Total assets: $46,550

* Total liabilities: $117,132

* Total stockholders' deficit: $(70,582)

* Cash and cash equivalents: $19,258 (June 30, 2024)

* Revenue - three months ended June 30, 2024: $11,766; six months: $21,152

* Gross profit - three months: $8,993; six months: $15,859

* Total operating expenses - three months: $18,339; six months: $36,595

* Net loss - three months: $(8,322); six months: $(6,326) (restated)

* Net loss per share - three months: $(4.34); six months: $(3.30) (basic and diluted)

* Accumulated deficit: $(221,335)

* Cash used in operating activities (six months): $(17,563)

* Convertible notes issued (RTW): $48,000 (proceeds); Convertible notes payable carried at $40,950

* Revenue Interest Financing liability (RTW): $39,000

* Earn‑out liabilities (fair value): $4,110

* Public warrant liabilities: $2,113

What's happening inside the company

* Restatement & controls - Management identified an error affecting Other comprehensive income, Other income (expense) and net income; restated Q2 2024 (and other periods). Management disclosed material weaknesses in internal control (staffing, segregation, IT controls) and is implementing remediation.

* Financing changes - Repaid the Fortress term loan and issued $48M of RTW convertible notes (April 2024) and completed a July 2024 public offering + RTW private placement; debt structure now includes fair‑value remeasurement items that drive large non‑cash income/expense swings.

* Reverse split - 1‑for‑25 reverse stock split effective Jan 3, 2025; financials retroactively adjusted.

* Regulatory headwind - ANSM (France) suspended sales of the Allurion Balloon (Aug 6, 2024); company withdrew product from France pending remediation; this is a commercial and reputational risk in a key market.

* Listing risk - NYSE notified the company of non‑compliance with $1.00 minimum average closing price (Aug 12, 2024); cure period applies - delisting risk if not cured.

Income statement - positives

* Strong gross margins: gross profit $15,859 on $21,152 revenue for six months (gross margin roughly in the mid‑70% range), indicating product gross economics are solid.

* Revenue remains recurring internationally: the Allurion Program continues to generate sales in multiple countries (France, Spain, U.K., and many others).

* Operating cost discipline in sales & marketing and R&D: both Sales & Marketing and R&D declined year‑over‑year (Q2 and YTD), reflecting cost actions to preserve cash.

Income statement - negatives

* Persistent net losses: net loss $(6,326) YTD despite gross profit - operating and non‑operating items still push the company into the red.

* Highly volatile non‑cash items: large fair‑value movements - Revenue Interest Financing, convertible debt, earn‑out and warrant remeasurements - produced swings in Other income (expense) (e.g., Total other income (expense) was $14,551 for the six months).

* Accumulated deficit and cash burn: accumulated deficit $(221,335) and operating cash use $(17,563) YTD; cash fell from $38,037 (Dec 31, 2023) to $19,258 (June 30, 2024).

* Restatement reduces confidence: historical restatements and identified material weaknesses undermine reliability until controls are remediated.

Near‑term catalysts & risks investors should watch

* France remediation outcome - whether ANSM will allow a return to market and on what conditions; impact on revenue and reputation.

* NYSE compliance - whether the company regains the $1.00 average closing price to avoid delisting procedures.

* Cash runway and financings - monitor cash balance, operating burn and any equity or debt raises (RTW notes limit share issuance until stockholder approval in some cases).

* Control remediation progress - hiring experienced accounting personnel, ERP and control fixes; auditors will review.

* Volatility from fair‑value remeasurements - continued mark‑to‑market on RTW notes, revenue interest financing and warrants will keep earnings volatile even if operations stabilize.

Bottom line

Allurion (NYSE: ALUR) still shows strong product gross economics but is navigating serious execution challenges: regulatory setbacks in France, restated financials driven by internal control gaps, a restructuring of debt that trades cash for complex fair‑value liabilities, and limited liquidity compared with near‑term cash burn. The investment case hinges on successful remediation (controls and regulatory), stabilization of revenues outside France, and the company's ability to secure additional capital or materially reduce cash burn.